News | January 16, 2025
Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
Morepen Laboratories approves hiving off of medical devices business
Morepen Laboratories approves hiving off of medical devices business
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
There was no casualty or loss of human life in the incidence
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Subscribe To Our Newsletter & Stay Updated
